$TGTX News

TG Therapeutics Announces Pharmacokinetic, Pharmacodynamic, Safety, And Tolerability Data From Phase 1 Clinical Trial Evaluating Subcutaneous Formulation Of Ublituximab As Compared To IV BRIUMVI

TG Therapeutics Publishes Post-Hoc Pooled Analysis Of Its Phase 3 ULTIMATE I, II Trials Of BRIUMVI To Treat Relapsing Forms Of Multiple Sclerosis

TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 Outlook

HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $70 Price Target

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

TG Therapeutics Says Topline Results From Phase 3 ENHANCE Trial Meets Primary Endpoint, Demonstrating Bioequivalent Drug Exposure Between Currently Approved BRIUMVI Day 1 And Day 15 Initiation Dosing And New Single Infusion On Day 1 Only

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics To Highlight BRIUMVI Data In Adults With Relapsing Forms Of Multiple Sclerosis At 2026 CMSC Annual Meeting

Multiple Sclerosis-Focused Biotech Quadruples Its Profit, Raises Sales Forecast

TG Therapeutics' (NASDAQ:TGTX) Earnings Aren't As Good As They Appear

Why TG Therapeutics (TGTX) Is Up 27.4% After Raising 2026 Revenue Guidance On BRIUMVI Strength

Assessing TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum

TG THERAPEUTICS INC (NASDAQ:TGTX) Screens as Affordable Growth Play with Strong Revenue Surge and Discounted Valuation

TG Therapeutics Q1 Earnings Call Highlights

TG Therapeutics, Inc. Q1 2026 Earnings Call Summary

TG Therapeutics (TGTX) Q1 2026 Earnings Transcript

HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $70

TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript

TG Therapeutics (TGTX) Q1 Earnings Lag Estimates

TG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Beat Revenue Guidance but Miss EPS Estimates